Oxford BioDynamics

Our Chief Data Officer introduced #EpiSwitchOrion at #PMWC2026—#OBD's groundbreaking platform to unlock clinical value hidden in #genomic data. Orion is powered by a model built on our deep expertise—core regulatory logic in the 'dark genome'. Book a demo: episwitchorion.com

Better triage in #ProstateCancer care: Identify who needs further evaluation— spare others unnecessary intervention. Grateful to partners like Jennifer Wright bringing #EpiSwitchPSE into real-world practice. #OBD #PSE #Urology #PrecisionMedicine

Peer-reviewed physician commentary by urologist @gpohlmanmd—“Reducing Unnecessary Prostate Biopsies Through Real-World Clinical Use of the #EpiSwitchPSE Blood Test”— highlights real-world #PSE use supporting confident patient risk assessment. obdx.co/p8k #OBD #urology

🎬Webinar in 100s — Here’s a highlight reel of key moments from “From Mystery to Measurable: The Science Behind the New #MECFS Blood Test.” Huge thanks again to Solve ME/CFS (@PlzSolveCFS) for hosting @OxBioDynamics & @uniofeastanglia. #OBD #EpiSwitch #ChronicFatigue #3Dgenomics

@Obdynamics CSO Dr Akoulitchev features in @pathologistmag discussing how #EpiSwitch 3D genomic biomarkers enable robust, practical #diagnostics, prognosis, disease monitoring & treatment-response assessment in complex diseases—now including #MECFS. #OBD 📖obdx.co/p8k

#PhysicianSpotlight: At #DoctorsStudio, Dr @LisbethRoyDO leads a prostate health program that goes beyond standard screening—with advanced diagnostics, longitudinal monitoring & personalized care. A key component, #EpiSwitchPSE, helps guide her informed #prostatecancer decisions.

Watch the video of our webinar on "The Science Behind the #MECFS Blood Test” to learn how #OBD developed breakthrough #EpiSwitch blood #biomarkers to help identify #chronicfatiguesyndrome (ME/CFS). Thanks for hosting, @SolveCFS 🙏 #PrecisionMedicine #3DGenomics #diagnostics #CFS

@OxBioDynamics is in @Nature—we're honoured to be featured in Nature on progress toward the first, long-overdue, accurate blood-test for #ChronicFatigueSyndrome (#MECFS). A breakthrough step for #OBD toward faster diagnosis and new therapeutic insights. 👉 obdx.co/j94

Great momentum at #LUGPA2026: @gpohlmanmd delivered the opening talk in the Global Prostate Cancer Congress #AdvancedDiagnostics session to a packed room. He highlighted pathways integrating #EpiSwitchPSE to support smart #prostatecancer care. @OxBioDynamics #urology #PSE #OBD

🚨Reminder: Register for our ME/CFS webinar hosted by @PlzSolveCFS. Learn how #OBD developed breakthrough blood markers to identify #ChronicFatigueSyndrome (#MECFS), a serious and often debilitating long-term illness characterised by extreme fatigue. 🗓️Jan 15, 2026 | 🕘9–10am PT

🎉 Happy New Year! We’re kicking off 2026 with an #EpiSwitchPSE podium presentation at the #LUGPA Global #ProstateCancer Congress. Urologist @gpohlmanmd will share real-world clinical data on integrating #PSE into routine care. See you there! #urology #OBD @94percent_com

New blog: “This #ProstateCancer Test is 270% Better Than #PSA”—Med Man Explains #PSE An #NHS GP & YouTuber explains why #EpiSwitchPSE is “so exciting.” His video hit 470K views in a month. 👉mypse.co/mdm Note: Med Man is independent & not affiliated with @OxBioDynamics

New on our #blog: the next generation of #cancer testing, in clinic and at home. Less invasive, more accurate options are emerging—but they’re not always talked about. What this means for #earlydiagnosis and better outcomes. 👇 mypse.co/fr7

Excited that our #EpiSwitchPSE abstract was accepted for a podium talk at the 2026 Global Prostate Cancer Congress. @gpohlmanmd will share compelling real-world data showing #PSE improves #prostatecancer detection & cuts unnecessary biopsies. @94percent_com #LUGPA #urology #OBD

2 normal MRIs. 2 negative biopsies. 1 aggressive #prostatecancer found with #EpiSwitchPSE. Standard diagnostics failed a 64yo patient with high #PSA. #PSE guided a 3rd biopsy, revealing Gleason 8 cancer. One blood test, a different outcome. #OBD 👉More at: 94percent.com

Today, the UK National Screening Committee chose not to recommend routine @NHSuk prostate cancer screening, based on standard testing tools. At Oxford BioDynamics, this is precisely why we are working to expand access to our accurate and convenient #EpiSwitchPSE blood test across the UK health system. As already demonstrated by clinical adoption in the private sector, #PSE reduces unnecessary biopsies by up to 79% while accurately detecting #prostatecancer — reducing adverse impacts on patients and supporting a more sustainable, cost-effective workflow. PSE is not just a potential tool in the #screening pathway as a reflex test — it is a vital triage test helping patients today after an initial suspicion of #cancer, and is backed by private insurers in the US and UK. The UK NSC reviews its recommendations when new evidence emerges. The committee’s advice to screen men who carry a BRCA gene variant is a positive step, but many believe it falls short of protecting Black men and those with a family history. This decision will not be the end of the screening conversation — we trust it will be the start of a new one that considers smarter, more accurate testing with tools in use today. #OBD #NHS #ProactiveForYourProstate

A UK doctor has shared an independent clinical overview of the #EpiSwitchPSE test by @OxBioDynamics (#OBD), comparing it with #PSA and highlighting its game-changing accuracy for #ProstateCancer. We appreciate doctors raising awareness for #menshealth. youtube.com/watch?v=O360HN…

🚨 Breakthrough in #MECFS research! Join our free webinar “From Mystery to Measurable: The Science Behind the New ME/CFS Blood Test” 🧬Learn how a 96% accurate test could transform diagnosis + treatment. 🗓️ Jan 15, 2026 | 9–10 am PT / 12- 1 pm ET. 🔗ow.ly/aZk450XiOeU

🏅Proud to see our publication in Cancers recognized as a “Highly Viewed Paper” by #MDPI. The meta-analysis highlights our #EpiSwitchPSE blood test as a compelling tool for early accurate #prostatecancer detection to address urgent global need. #OBD @OxBioDynamics @MDPIOpenAccess